Home

The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).

SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.


Visitors and news

EMERGENCY: Coronavirus disease (COVID-19) Pandemic

16/03/2020
Regular updates on the coronavirus disease (COVID-19) outbreak are available at the WHO website.

New publication: Efficacy of Point-of-care Thermal Ablation Among High-risk Human Papillomavirus Positive Women in China

09/09/2020
In this study, the authors evaluated the efficacy of thermal ablation in treatment of CIN detected through high-risk HPV screening in China. They found that thermal ablation is effective to treat CIN as well as to clear the high-risk HPV infection. HPV test could be a suitable surveillance test for women following treatment. This point-of-care ablative technique improves the access to treatment of cervical premalignant lesions in LMICs.
View the article

New academic initiative of Indian College of Obstetricians & Gynaecologists (ICOG)

08/09/2020
Dr Partha Basu, head of the screening group, supports the new academic initiative of Indian College of Obstetricians & Gynaecologists (ICOG) and will participate to the inauguration of the Journal club on 9th September 2020 at 5pm Indian time.
Free registration

New fellowships: Lara Rodrigues Da Matta Calegari

01/09/2020 – 30/09/2020
Ms Lara Rodrigues Da Matta Calegari from the Faculdade Evangélica Mackenzie do Paraná, Brazil, has joined the Screening Group at IARC as an intern. Lara will participate in research activities on health inequalities research related to cancer screening programmes, evaluating data on measurable indicators of inequalities in access to screening in low and middle income countries.

New commentary: The Quebec mixed-schedule HPV vaccination policy will maximize public health gain

01/09/2020
In this commentary published in HPVWORLD, Dr Partha Basu discusses the Quebec's Mixed HPV vaccination schedule introduction: The revised vaccination schedule has allowed the Quebec Government to save $ 3 million a year that they have utilized to extend the vaccination to the boys in Grade 4 of primary school. View the commentary.

All visitors and news


Scientific papers

Zhao X.L., Liu Z.H., Zhao S., Hu S.Y., Muwonge R., Duan X.Z., Du L.J., Su C.F., Xiang X.E., Zhang X., Pan Q.J., Qiao Y.L., Sankaranarayanan R., Zhao F.H., Basu P. Efficacy of Point-of-care Thermal Ablation Among High-risk Human Papillomavirus Positive Women in China. Int J Cancer. 2020 Sep 7.
PMID: 32895912
Baena A., De Vuyst H., Mesher D., Kasubi M., Yuma S., Mwaiselage J., Zouiouich S., Mlay P., Kahesa C., Landoulsi S., Hernandez M.L., Lucas E., Herrero R., Almonte M., Broutet N. Reproducibility of a rapid human papillomavirus test at different levels of the healthcare system in Tanzania: the AISHA study. Cancer Epidemiol Biomarkers Prev. August 20 2020.
PMID: 32856600
Basu P. Healthcare Systems Need to be Organized to Fight two Pandemics Simultaneously. Asian Pacific Journal of Cancer Care, 5(S1), 1-3.
PMID:

All scientific papers

IARC, 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France - Tel: +33 (0)4 72 73 84 85 - Fax: +33 (0)4 72 73 85 75
© IARC 2020 - Terms of use  -  Privacy Policy.